Skip to main content

Table 1 Patient and tumour characteristics

From: Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

Age at diagnosis

Years

   Median

79

   Range

63 to 86

Tumour size

n (%)

   T2

11 (73)

   T3

1 (7)

   T4

3 (20)

Lymph node status

n (%)

   +ve

2 (13)

   -ve

13 (87)

Histological grade

n (%)

   1

1 (7)

   2

9 (60)

   3

4 (26)

   Unknown

1 (7)

Progesterone receptor

n (%)

   +ve

11 (73)

   -ve

4 (27)

HER2

n (%)

   +ve

2 (13)

   -ve

13 (87)